Next Phase Newsletter

A venture capital firm headquartered in Western Europe is focused on enabling technology within life sciences and healthcare. firm will make initial investments ranging from at a minimum of 1M euro, and will make follow-on investments in total adding up to 5M-7M euro. The firm will invest in Seed-Series B companies. The firm will be launching their new fund in 2025. The firm aims to be a meaningful investor, looking to lead deals, but will also co-lead and can syndicate in certain cases. The firm will generally invest within Western Europe. 
 
The firm will invest in diagnostics, medical devices, and digital health. The firm is not open to investing in therapeutics. The firm is not interested in invasive devices and will not invest in Class 3 and some Class 2 devices. The firm will look at companies with IND approval and in early-clinical stages. 
 
The firm does not have any specific team requirements. The firm considers themselves active, hands-on investors and will typically require a board seat. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A corporate venture arm of a corporation headquartered in Asia with offices in the US is mandated to invest in venture stage companies across several sectors including the Life Sciences. The firm started investing in the Life Sciences in 2012 and has made 20 investments thus far. The firm can allocate up to USD 20 million depending on the stage of the company. The firm can invest globally and is actively seeking new investment opportunities. 
 
In the Life Sciences, the firm is interested in therapeutics, medical devices, diagnostics, and digital health. The firm seeks technologies that are differentiated and address a major unmet medical need. The firm is agnostic to the stage of development and therefore will consider therapeutics in pre-clinical and devices/technology in concept stage. The firm focuses on products that have a clear and fast path to market. Historically, the firm invested in drug discovery, diagnostics for tumors, and devices for COPD and POAG. 
 
The firm is looking for companies with experienced management teams. The firm is willing to both lead and act as a member of a syndicate. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A venture capital firm of a family-owned service provider seeks investments in Seed to Series A/B, with an initial check ranging between 3-7 million Euros. Follow-on investments are possible, and the firm may invest up to 15 million Euros throughout the life cycle. The firm is open to both leading and co-investing. The firm focuses on opportunities in Europe, UK and US. 
 
The firm is interested in early-stage therapeutic technologies. The firm is agnostic regarding modalities and indications, and is open to exploring different types of therapeutic assets. Additionally, the firm has invested in orphan drugs. While there is no strict mandate for the development phases of assets, having at least in-vivo data would generally be preferred. 
 
There are no specific requirements for companies’ management team. 
 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A venture arm of a global pharmaceutical company with a market cap exceeding $11 billion, is actively investing in the early-stage healthcare sector. The firm focuses on pre-seed/seed-stage opportunities, with the initial investment range spanning 0.5-2 million. The firm is interested in opportunities globally with a focus in the US. The firm is open to both leading and co-investing and will consider board seats when leading the round. While the firm is mostly finance driven, the firm is able to bring in the strategic perspective if deemed necessary. 
 
The firm seeks companies with innovative sciences addressing highly unmet needs. The firm is focused on therapeutic, including cell and gene therapy, small molecules, radiopharmaceuticals, CRISPR, and data-driven technologies such as AI-driven drug discovery. The firm is interested in oncology, neurology, and rare diseases. Less invasive diagnostic technologies are also within the scope. The firm mostly works with companies in the preclinical to phase I stages. 
 
The firm focuses on finding promising science backed by strong IP. As an active investor, the firm supports portfolio companies through its extensive network and resources.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

An early-stage MedTech venture capital fund prioritizes opportunities in interventional cardiology, structural heart, peripheral vascular, electrophysiology, and related fields. Check size range from $500k – $2M, typically in early-stage Seed and Series A financings. The investment team includes successful serial medical device entrepreneurs and investors, and is supported by a world-class advisory team including cardiovascular KOLs. 
 
The firm has recently launched a new healthcare fund in collaboration with a digital health-focused VC, resulting in the firm’s focus shifting more to Healthcare IT and Digital Health, with a specific focus on how healthcare delivery has changed during the COVID 19 pandemic. Examples of the subsectors of interest are: remote care, Healthcare IT for hospital efficiency, and response infrastructure systems. The firm is opportunistic in terms of indication. 
 
The firm looks for management teams with domain experience, and is comfortable with working with incomplete or scientific founding teams. The firm prefers to take a board seat into companies following investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A multi-family venture fund based in the US is an active investor in the medical device sector, and is interested in opportunities in the western United States. Initial investments are typically about $150,000 with the potential for follow-on investments totaling $1 million and may be structured as equity or as debt. The firm offers support and expertise to portfolio companies but does not seek a board seat. 
 
The firm is interested in medical technology and lab equipment, including electro-mechanical medical devices, active implantable devices, and surgical instruments. The firm invests only in companies that have already developed a prototype of their product,  filed a patent application and have animal data. 
 
The firm seeks to invest in strong management teams with prior experience in the medical device industry. The firm prefers to make investments with the potential to exit within 3-4 years. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

 A healthcare venture capital firm established in 2019 with offices in US and China focuses on early- and growth-stage biotech and medtech companies. Initial check sizes range from USD $3-5M for Series A and B, and USD $10M+ for Series C and beyond. Currently, the firm has 3 funds under management, exceeding USD $600M AUM. The current fund is focused on U.S. companies. The firm can act as a lead or co-investor. 
 
The firm is especially interested in biotherapeutic innovations and would like to see positive data that has come out of clinical trials. The firm is open to all indications but has a high interest in oncology, immunology, and chronic disease. 
 
The firm likes to see experienced management teams, especially those with founders that have had previous success. The firm may take a board or observer seat on a case-by-case basis. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.